Oklo Inc. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2025. Oklo Inc. is an advanced nuclear energy company developing "Aurora" fast fission powerhouses (15–75 MWe) designed to run on fresh, recycled, or down-blended nuclear fuel. The company operates on a build-own-operate model, selling electricity and heat directly to customers via Power Purchase Agreements (PPAs). Oklo is classified as an Emerging Growth Company (EGC) and ceased to be a "smaller reporting company" as of December 31, 2025, though it utilized scaled disclosures for this report.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Revenue | $0.0 | $0.0 |
| Total Operating Expenses | $139.3 | $52.8 |
| Net Loss | $(105.7) | $(73.6) |
| Cash, Cash Equivalents, & Marketable Securities | $1,412.5 | $227.8 |
| Net Cash Used in Operating Activities | $(82.2) | $(38.4) |
| Net Cash Provided by Financing Activities | $1,263.2 | $301.4 |
| Accumulated Deficit | $(240.8) | $(135.1) |
Note: The company has no commercial revenue. Operating expenses increased significantly due to headcount growth and professional services. Financing activities were driven by equity issuances totaling approximately $1.26 billion in net proceeds.
Material Changes vs. Prior Period
- Acquisition: Acquired Atomic Alchemy Inc. in February 2025 for approximately $28.4 million (cash and stock) to expand radioisotope production capabilities.
- Capital Raises: Raised significant capital through a June 2025 public offering ($460 million gross) and two "at-the-market" (ATM) programs in 2025 ($840 million gross combined), resulting in a substantial increase in cash reserves.
- Expense Growth: Operating expenses nearly tripled from $52.8 million in 2024 to $139.3 million in 2025, driven by a 120% increase in R&D and a 208% increase in General and Administrative (G&A) costs.
- Regulatory Milestones: Received DOE approval for the Nuclear Safety Design Agreement for the Aurora-INL powerhouse and completed a fast-spectrum plutonium criticality experiment.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Management expects 2026 operating cash usage to range between $80 million and $100 million.
- Investing activities for 2026 are projected to range between $350 million and $450 million.
- The company targets the deployment of its first commercial powerhouse in 2028.
- Meta Agreement: Entered a prepayment agreement with Meta Platforms, Inc. (January 2026) to develop a 1.2 GW power campus in Pike County, Ohio.
- DOE Partnerships: Selected for three projects under the DOE Reactor Pilot Program (RPP), including the Aurora-INL powerhouse and a radioisotope pilot facility.
- Regulatory Uncertainty: No NRC or DOE licenses have been issued for commercial operation; approval is not guaranteed.
- Fuel Supply: Reliance on High-Assay Low-Enriched Uranium (HALEU) and plutonium, which are not currently available at scale domestically.
- Construction Costs: First-of-a-kind projects face significant risks of cost overruns and delays due to supply chain constraints and lack of commercial precedent.
- Liquidity: The company expects to incur losses until commercial viability is achieved and will require additional funding.
Investor Verification Checklist
- Regulatory Pathway: Verify the status of the Custom Combined License Application (COLA) with the NRC and the specific authorization timeline for the DOE pathway at Idaho National Laboratory.
- Fuel Security: Confirm the availability and cost of HALEU and the progress of the fuel recycling facility in Tennessee, as fuel supply is a critical bottleneck.
- Customer Commitments: Distinguish between non-binding Letters of Intent (LOIs) and binding Power Purchase Agreements (PPAs); currently, no binding PPAs for commercial power delivery exist.
- Capital Runway: Assess whether the $1.4 billion in cash and marketable securities is sufficient to fund the projected $350–$450 million in 2026 investing activities and ongoing operations without further dilution.
- Acquisition Integration: Review the integration progress and revenue potential of the Atomic Alchemy radioisotope business.